This is the first drug-eluting catheter designed specifically to treat atherosclerosis in arteries located below the knee, the company said.
IN.PACT features FreePac, a proprietary coating that frees and separates paclitaxel molecules and facilitates their absorption into the wall of the artery.
Invatec plans to launch a randomized trial, the IN.PACT Deep study, in the first half of 2009, to provide additional data about the effectiveness of the new treatment concept.